
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$80.38
+$0.14 · +0.17%
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Previous close
$80.38
+$0.14 · +0.17%
After-hours
$80.38
$0.00 · 0.00%
Sep 16, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Day range
Current $80.38
52-week range
Current $80.38
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
71
Undervalued
Sentiment
71
Bullish
Risk
31
Moderate Risk
Momentum
60
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfolio encompasses a range of catheters, including angioscopes, which are fiberoptic tools for internal blood vessel visualization; embolectomy catheters for removing blood clots from arteries or veins; occlusion catheters that temporarily halt blood flow; perfusion catheters for infusing blood and other fluids into the vasculature; and thrombectomy catheters, featuring a silicone balloon for extracting venous thrombi. The company also furnishes carotid shunts, designed to temporarily redirect blood flow to the brain during carotid endarterectomy surgery to clear arterial plaque. Another offering is radiopaque tape, a medical-grade adhesive applied externally to help interventionists precisely cross-reference skin locations with underlying anatomical features like vessels or lesions. Further products include valvulotomes, instruments used to cut or disrupt valves within the saphenous vein, enabling it to function as an arterial bypass to carry blood past diseased arteries to the lower leg or foot. Additionally, LeMaitre supplies vascular grafts for bypassing or replacing compromised arteries. Moreover, the company provides vascular and cardiac patches for post-surgical vessel closure. Its closure systems employ titanium clips for connecting vessels, offering an alternative to traditional sutures. Products are distributed via both its direct sales force and a network of distributors. Founded in 1983 as Vascutech, Inc., the company rebranded as LeMaitre Vascular, Inc. in April 2001. It is headquartered in Burlington, Massachusetts.
Day range
Current $80.38
52-week range
Current $80.38
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 249.6M USD | 219.86M USD | 193.48M USD | 161.65M USD | 154.42M USD |
| Cost of goods sold | 71.06M USD | 68.96M USD | 66.44M USD | 56.76M USD | 53.04M USD |
| Gross profit | 178.54M USD | 150.9M USD | 127.05M USD | 104.9M USD | 101.38M USD |
| Research and development | 14.14M USD | 15.65M USD | 16.97M USD | 13.29M USD | 11.8M USD |
| Selling, general, and administrative | 96.49M USD | 83M USD | 72.89M USD | 61.67M USD | 53.16M USD |
| Operating expenses | 110.63M USD | 98.65M USD | 90.34M USD | 78.07M USD | 64.96M USD |
| Interest income | 13.09M USD | 4.95M USD | 3.08M USD | 986K USD | 197K USD |
| Interest expense | 5.18M USD | 205K USD | — | — | 2.22M USD |
| Depreciation and amortization | 10.42M USD | 9.67M USD | 9.52M USD | 9.43M USD | 9.48M USD |
| Operating income | 67.91M USD | 52.26M USD | 36.71M USD | 26.83M USD | 36.43M USD |
| Net income | 57.73M USD | 44.04M USD | 30.11M USD | 20.64M USD | 26.91M USD |
Company facts updated Sep 17, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$115
43.07% upsideCash distributions grouped by calendar year; partial years are marked.
$0.80
2025 complete year+81.8% since 2021
2026 partial: $0.75
$0.44
2,021
$0.50
2,022
$0.56
2,023
$0.64
2,024
$0.80
2,025
$0.75
2,026*
* Partial calendar year in the available dividend history.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Aug 20, 2026 | $0.25Quarterly | Aug 20, 2026 | Sep 3, 2026 |
Dividend | May 21, 2026 | $0.25Quarterly | May 21, 2026 | Jun 4, 2026 |
Dividend | Mar 12, 2026 | $0.25Quarterly | Mar 12, 2026 | Mar 26, 2026 |
Dividend | Nov 20, 2025 | $0.20Quarterly | Nov 20, 2025 | Dec 4, 2025 |
Dividend | Aug 21, 2025 | $0.20Quarterly | Aug 21, 2025 | Sep 4, 2025 |
Dividend | May 15, 2025 | $0.20Quarterly | May 15, 2025 | May 29, 2025 |
Ex-dividend Aug 20, 2026
$0.25
Quarterly
Record Aug 20, 2026 · Payment Sep 3, 2026
Ex-dividend May 21, 2026
$0.25
Quarterly
Record May 21, 2026 · Payment Jun 4, 2026
Ex-dividend Mar 12, 2026
$0.25
Quarterly
Record Mar 12, 2026 · Payment Mar 26, 2026
Ex-dividend Nov 20, 2025
$0.20
Quarterly
Record Nov 20, 2025 · Payment Dec 4, 2025
Ex-dividend Aug 21, 2025
$0.20
Quarterly
Record Aug 21, 2025 · Payment Sep 4, 2025
Ex-dividend May 15, 2025
$0.20
Quarterly
Record May 15, 2025 · Payment May 29, 2025
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Core S&P Small-Cap ETFIJR102.47M0.10%106.82B USD0.06%$139.46-0.42%
First Trust SMID Cap Rising Dividend Achievers ETFSDVY79.59M0.71%11.24B USD0.58%$41.89-0.92%
Vanguard Morningstar Total Stock Market ETFVTI55.68M0.00%2.3T USD0.03%$371.26-0.42%
iShares Russell 2000 ETFIWM46.06M0.06%79.89B USD0.19%$283.92-0.43%
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH23.92M0.12%256.42M USD0.25%$49.9495+0.02%
Vanguard Extended Market ETFVXF19.56M0.02%95.4B USD0.05%$234.39-0.32%
iShares Russell 2000 Growth ETFIWO16.45M0.12%14.31B USD0.24%$361.11-0.03%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM15.7M0.10%16.14B USD0.03%$54.43-0.42%
iShares Core S&P Small-Cap ETFIJR
First Trust SMID Cap Rising Dividend Achievers ETFSDVY
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.